Just reported
From Edwards Lifesciences's results release of 4 नवंबर 2026; its quarterly report has since been filed.
Actual
$1.72B
+10% y/y
-1.5% q/q
Guided
$1.67B
midpoint
Actual
$0.53
+6.0% y/y
+26% q/q
Guided
—
No guide given
Actual
$299.1M
-2.6% y/y
-42% q/q
Guided
—
No guide given
Q4 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →आमदनी के हिस्से nine months ended September 30, 2026 के अनुमान हैं, किसी दाख़िल रिपोर्ट के आँकड़े नहीं।
SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.
SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.
Edwards makes devices that replace or repair damaged heart valves. Some are delivered through a catheter, a thin tube passed through a blood vessel, while others are implanted during open-heart surgery. Hospitals and heart specialists use these devices to treat diseases affecting the aortic, mitral, and tricuspid valves.
Edwards Lifesciences Corporation की अपनी रिपोर्टों से बना, जो अमेरिकी प्रतिभूति और विनिमय आयोग (SEC) में दाखिल की गईं। आँकड़े जैसे बताए गए, और प्रति-शेयर इतिहास आज के शेयर आधार पर पुनर्गणित। यह एक व्यवसाय का वर्णन है — यह निवेश सलाह नहीं है और न ही कुछ खरीदने या बेचने की सिफ़ारिश।
EW · NYSE · Healthcare · Medical Devices
$107.15+1.3%13 नव॰ बंद भाव
30 सितंबर 2026 तक के आँकड़े, 4 नवंबर 2026 को दाखिल 10-Q से
Edwards Lifesciences sells catheter-delivered heart valves and repair devices, plus surgical replacement valves, to hospitals treating people with heart valve disease.
कंपनी का अनुमान: वित्त वर्ष 2026 की तिमाही 4 के लिए $1.7B से $1.8B का राजस्व — एक साल पहले से 8.9% अधिक
The themes Edwards Lifesciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A+
भाव के नीचे की पट्टी हर तारीख की ग्रेड दिखाती है, जो सिर्फ़ उस समय तक सार्वजनिक दस्तावेज़ों से बनी है।
Edwards Lifesciences Corporation के ग्रेड इतिहास की 41 तिमाहियों में से 2 दिखाई जा रही हैं। बाकी 39 अक्टूबर 2016 तक जाती हैं।